ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GEN Genuit Group Plc

441.00
7.00 (1.61%)
Last Updated: 10:47:39
Delayed by 15 minutes
Genuit Investors - GEN

Genuit Investors - GEN

Share Name Share Symbol Market Stock Type
Genuit Group Plc GEN London Ordinary Share
  Price Change Price Change % Share Price Last Trade
7.00 1.61% 441.00 10:47:39
Open Price Low Price High Price Close Price Previous Close
445.00 434.50 445.00 434.00
more quote information »
Industry Sector
INDUSTRIAL ENGINEERING

Top Investor Posts

Top Posts
Posted at 08/4/2021 15:43 by philanderer
Investors Chronicle, march 16th..

Polypipe is also keeping in step with the Zeitgeist by offering a product that circulates cool filtered air around classrooms.

Other areas to note are increasing exports of water management products to areas with natural shortages of clean drinking water

Rec: Hold
Posted at 15/1/2006 14:21 by elgordo
This week's Investors Chronicle has an article about five privately held tech companies that can be invested in indirectly, of which the fifth is Sphere (via GEN, of course). Got dragged away from Sainsburys magazine rack to look at more important things like the weekly food shop before I got a chance to read it, though. Anyone else seen it?
Posted at 19/12/2005 08:49 by maytrees
Indy comments today:
"...awards fuels interest in CMR

CMR Fuel Cells, which claims to have developed a revolutionary type of fuel cell technology, will debut on AIM this week. Investec Securities, the group's broker, has had little trouble raising money for the company. In fact, it was forced to increase the size of the fund raising from £8m to £10-12m because of investor demand. This will value the company at about £35m.

CMR, founded by Michael Priestnall and Michael Evans, has developed a fuel cell which converts methanol into electricity. To start with, the group plans to target the consumer electronics markets where existing batteries are struggling to produce the performance increasingly required by users of mobile phones and laptops. CMR says its fuel cells can produce more power than anything currently available of that size.

The group has picked up an impressive array of awards over the past year. These have included the 2005 Carbon Trust Overall Innovator of the Year award and the Carbon Trust Small Business award. It was also named by Harvard Business School as one of the 25 companies most likely to change the world by 2010. CMR is definitely one for investors to keep an eye on in the months after its float."

I hold gen - dyor
Posted at 15/7/2005 08:17 by maxwellsdemon
RNS Number:9021O
Generics Group AG
15 July 2005


Generics' award winning spin-out CMR Fuel Cells Ltd successfully completes
Series B financing

The Generics Group AG, a leading integrated technology consulting, development
and investment organisation, is pleased to announce that its spin-out company,
CMR Fuel Cells Ltd ('CMR'), winner of the 2005 Carbon Trust Innovation Award,
has successfully completed a Series B financing from a syndicate of
institutional and individual investors.

Generics invested #250,000 in the series B round and maintains a 16.4% equity
stake in CMR post the financing. Co-investors in the series B round include
Herald Ventures II LLP acting through its general partner and manager Herald
G.P. II Limited, Conduit Ventures and the Carbon Trust in addition to other
funds managed by Generics. The BVCA value of CMR in Generics' portfolio post
funding is #1.0m (Q1 2005 CMR BVCA #0.1m).

The funding is a major step forward in CMR's mission to make mass-market fuel
cells commercially viable for the first time. CMR's world-leading technology
gives OEMs and manufacturers the option to integrate cost effective, long
running and energy efficient fuel cell solutions into a wide range of consumer
electronic products. The funds will be used to strengthen and accelerate CMR's
technical and commercial development.

"We are tremendously excited to be working with such a high-capability group of
investors who share our vision of CMR technology driving the uptake of fuel
cells in mass-market portable electronics. They bring financial, strategic and
commercial resources which significantly enhance CMR's ability to realise our
goal" said John Halfpenny, CEO of CMR Fuel Cells.

Martin Frost, Managing Director, The Generics Group, added "I am delighted that
the technical and commercial progress of CMR over the last 18 months has been
recognised in the Series B financing. We believe that CMR will become a leading
supplier of fuel cell products based on revolutionary stack architecture. In the
short term this will enhance the BVCA valuation of our portfolio by around #1m.
In the longer term CMR is capable of creating significant wealth for itself, its
customers and its investors."
Posted at 02/5/2005 20:06 by maxwellsdemon
rambutan,

You could be right. Here is more on the Red Herring guff:

CMR Fuel Cells selected for prestigious Red Herring’s Top 100

12 April, 2005 - CMR Fuel Cells Ltd, today announced that it has been selected as one of Red Herring’s Top 100 private companies to watch in 2005. The Cambridge based company is developing pioneering fuel cell technology, set to deliver the low-cost, long run-time power solutions that today’s portable electronic products demand.
Through its unique, patented fuel cell technology CMR will make mass-market fuel cells commercially viable for the first time, reducing the cost of a fuel cell stack by up to 80% and the size by up to 90%. CMR’s products can be built using printing or roll-to-roll techniques – improving reliability and further reducing costs.
Every year, Red Herring's Top 100 sets the standard as the technology industry’s definitive list of private companies impacting the market place. The editorial team at Red Herring, the leading magazine of business technology and innovation, has selected companies that have demonstrated outstanding achievements since their inception, representing the most instrumental players in leading the technology industry.

Red Herring’s editorial staff rigorously evaluated more than 600 private companies through a careful analysis of financial data and subjective criteria, including quality of management, execution of strategy, and dedication to research and development. “We are delighted that Red Herring has recognised the validity of our vision of CMR delivering the promise of instant re-charge, long run-time and low cost to the portable electronics industry,” said John Halfpenny, CEO of CMR Fuel Cells Ltd. “We are poised to enable a new generation of products, for the first time exploiting the massive increases in power available from fuel cells when compared with traditional battery power.”

“Our list shows that despite obstacles posed by regulations, bureaucracy and tradition, innovation and entrepreneurship continues to thrive in Europe,” said Red Herring editor-in-chief Joel Dreyfuss. Red Herring’s lists of top private companies are an important part of the magazine’s tradition of identifying new and innovative technology companies and entrepreneurs. Companies like Google and eBay were spotted in their early days by Red Herring editors as those that would change the way we live and work. This is the first time that Red Herring magazine has compiled a list focused exclusively on the most promising start-ups in Europe.

About CMR Fuel Cells

CMR Fuel Cells Limited is a UK developer of fuel cell stacks for portable and small stationary power generation applications. The company plans to become a leading supplier of fuel cell technology and products, based on its simple but revolutionary stack architecture and through its relationships with other key organisations.

CMR Fuel Cells Limited was incorporated in October 2003, based on technology developed over the preceding four years at the Generics Group in Cambridge, UK. The company is owned by the management team, Conduit Ventures Limited, Carbon Trust Investments, and the Generics Group. Conduit Ventures is a specialist venture capital fund focusing on fuel cells backed by Johnson Matthey, Shell Hydrogen, Mitsubishi, Danfoss, and Solvay.

Carbon Trust Investments is a leader in clean energy investing and is funded by the UK government. Generics is a leading European technology and management consultancy located in Cambridge, UK.

For more details, please visit www.cmrfuelcells.com

About Red Herring

Red Herring, Inc., founded in 1993, is a media company whose mission is to cover innovation, technology, financing and entrepreneurial activity. Its staff of award-winning journalists tell readers what's first, what matters and most importantly, why.

Red Herring is dedicated to thorough research, relevant metrics deep financial analysis, indepth reporting, crisp writing and thoughtful debate. We are a skeptical, intelligent and trustworthy source of information in technology business. Our primary obligation is to provide the most relevant, honest and independent information and analysis to our audience, with the conviction that an exceptional editorial product is the best catalyst for success and the best way to serve our advertisers and investors. Our content is original, compelling and actionable for industry executives and entrepreneurs.

A privately held company, Red Herring, Inc. is headquartered in Belmont, California. For more information visit
Posted at 28/2/2005 11:14 by rambutan2
not a bad return so far but could be much more to come. interesting to see herald and artemis amongst the investors. and in full...

Sphere Medical Holding Limited secures £4,000,000 in next round financing

The Generics Group AG, a leading integrated technology consulting, development
and investment organisation, is pleased to announce that one of its portfolio
companies, a joint venture with Siemens Technology Accelerator GmbH, has
successfully raised a further £4,000,000 with a first closing of £3,196,250
(before expenses) from a series of institutional investors for further
development.

Sphere Medical Holding Limited ('Sphere') was incorporated to develop a series
of unique chip-based microsensors for use in intensive care medicine.

The funding was organised by Oakes, Lyman & Co Ltd with additional participation
by Springhill Bioventures, Herald Ventures, Artemis and Hotbed.

The size of the global in vitro diagnostic market is estimated at $23 billion
per annum, growing steadily each year particularly in the point-of-care sector
in which Sphere will operate. Sphere will be targeting the on-line measurement
of physiological parameters and anaesthetics segments of the market, which are
growing strongly.

The financing round capitalises the company at £7m. Generics has invested
£155,000 as part of the financing. Post the completion of the financing and
conversion of existing loans, Generics holds a 10.56 % fully diluted interest in
Sphere Medical.

Martin Frost, Managing Director of Generics, commented:

'We are very proud to see Sphere receive such wide spread support for the
development of its technology. In many ways we feel that this is a great
demonstration of our consultancy divisions' proficiency in identifing potential
commercial opportunities in under utilised intellectual property. Moreover,
taking Sphere to this point of its development demonstrates the way in which our
consultancy, development and investment divisions cooperate to fully capture the
commercial potential of new technologies.

We are delighted for the Sphere team and look forward to reporting on their
future progress.'
Posted at 24/3/2004 18:21 by rambutan2
needlestick injury normally refers to the investors of the companies who try and launch safety devices! lets hope gens version has better luck.

wonder if theyve now got enough to avoid the fund raising? or are they aiming to launch it off the recent better news?
Posted at 28/1/2004 12:32 by rambutan2
heres one that came good. pity we had to dump the shares...

Synaptics (SYNA : NASDAQ : US$19.70)
Net Change: 3.50, % Change: 21.60%, Volume: 1,358,900
Looking for a hands-on investment? Synaptics sparked the interest of many
investors Friday after saying its December quarter earnings nearly
doubled, beating analysts' expectations, with a 42 percent revenue boost
that was driven by sales of interface products used in notebook computers.
The maker of TouchPad systems that act as a mouse and control the cursor
of notebooks, PDAs and MP3 players recently introduced the SpeakerPad,
which doubles as both the TouchPad and speaker in a notebook computer.
Cooo-eeellll. So where is Synaptics going from here? The company says the
March quarter will be in parity with the December quarter sales, and
expects "the June quarter to be higher than in March."
Posted at 01/10/2003 14:36 by maxwellsdemon
Press Releases
Four Generics' companies in Sunday Times ARM Tech Track 100
01 October 2003

The Generics Group (Generics), the integrated technology consulting, development and investment organisation, today announced that four of its portfolio companies were selected in the Sunday Times index of the top 100 fastest growing technology companies: with two of the companies, Voxar Ltd and Cambridge Positioning Systems Ltd, in the top 20.

The companies, advised and managed by Generics Asset Management Ltd (GAML), are:

- Voxar Ltd, an industry leader in the development of software products for visualizing medical scanner data.

- Cambridge Positioning Systems Ltd, which supplies high accuracy location technology for network equipment and handset vendors and chipmakers.

- Westica Ltd, a leading supplier of digital radios to mobile operators, emergency services, utilities, broadcasters, and private network operators.

- Imerge Ltd, a Generics' spin-out, is a recognised leader in Internet-connected hard disk-based audio products and Media Appliances.

Martin Frost, Managing Director of Generics said: "Generics is proud of its reputation as one of the earliest stage technology investors in Europe. In each of the companies selected for the index, Generics played important roles in either the company's creation or development as well as financing growth. These are key elements of Generics' business model, which has served Generics and its investee companies well since 1986."


--------------------------------ends-------------------------------
Notes for Editors:

The Generics Group
The Generics Group (Generics) is a leading integrated technology consulting, development and investment organisation, with an international reputation for successfully commercialising emerging science and technology.

Generics invests in and develops technologies that underpin the future of the widest range of industries. Its key areas of expertise include: engineering, materials, telecommunications, life sciences, business innovation and electronics.

Generics' facilities include state-of-the-art laboratories and are located in Europe in Cambridge, Frankfurt, Z├╝rich, Switzerland and Stockholm; and in Boston and Baltimore in the USA. Generics has over 200 employees, of which more that half are high-calibre technology professionals.

THE SUNDAY TIMES ARM TECH TRACK 100
For more information about The Sunday Times ARM Tech Track 100, go to the press release section
Posted at 01/9/2003 13:31 by rambutan2
bit of extra meat in this from the cambridge news...

Losses down as Generics Group heads for profit

Generics Group says it is heading back towards profit after the worst period in the consulting industry in 30 years.
The Harston-based group, which says it is still in negotiations over a possible sale, announced interim results showing sales up from £6.2m a year ago to £6.8m, and losses down from £8.7m to £6.9m.

At the same time the group has announced restructuring that sees the business split into four distinct areas in a bid to achieve greater transparency for investors.

Peter Hyde, who came out of semi-retirement to see the group through its darkest hour, steps down as chief executive and will retire again at the end of the year.

As from September 1, Simon Davey takes over as chief executive of the consulting business and development of intellectual property, while Martin Frost becomes managing director and chief financial officer of the holding company.

Mr Frost will also be responsible for a new property company within the group, managing buildings at Harston worth £16.5m. He will also be in charge of the management of group investments in spin-out companies.

Chris Coghill will remain in charge of asset management involving outside investments.

Speaking at a special briefing held at Harston yesterday, Mr Hyde, who says he will soon be spending his days restoring an old tractor and playing with his grandchildren, explained why the group was being re-structured:

"We want the stock market to see how the company really works. We want to show that an operating loss can represent a hot investment."

He added: "This year, Scientific Generics is highly profitable, but we are hoist by the rather peculiar structure of our business."

The financials have been helped this half by the sale of Generics' holding in former spin-out, Synaptics. The sale has brought in £3.1m at a profit of £1.4m. Generics has also bought the assets of another former spin-out, Quantum Beam, from the liquidator for £160,000.

Unsurprisingly, the value of the group's investment portfolio is down to a third of what it was a year ago at £11.1m compared with £34.4m.

There has been an 11% reduction in operating costs, from £14.2m a year ago down to £12.6m, brought about largely as a result of salary cuts among the higher paid employees, decision to dispense with an HR supremo at director level, and reduction in travelling.

Regarding a possible sale, Mr Hyde said: "Talks are ongoing. We were obliged to say something due to the share price changing, but it was something we might otherwise not have said.

"We have discovered that the City is an extraordinarily leaky place when it comes to share price movement."

However, he said another announcement would be made in September regarding long-term plans.

Asked whether he and his fellow directors had ever thought of throwing in the towel during what he described as the worst period in consulting in 30 years, Mr Hyde answered an emphatic "never".

Generics is 49% owned by Ikea's Swedish holding company, with Generics' founder, Gordon Edge, holding 10%. Mr Hyde said the company had always had strong support from its majority shareholders.

* Simon Davey is 52 and a graduate of Churchill College, Cambridge, where he read natural sciences. He worked at Metals Research in Melbourn before joining PA Consulting, ran his own business for a while, joined Coopers & Lybrand and came to Generics in 1995.

His other claim to fame is as the UK's most successful non-professional racing driver in terms of championships won - 13 titles - and he continues to race in Classic Formula Ford events.

* Martin Frost, 40, is a graduate of Christ's College, Cambridge where he read history. He is a chartered accountant and has worked for Simon Engineering in Manchester, and GEC Marconi.

His career has spanned the globe and he has been much involved in merger and acquisitions work.

He was head-hunted to join Generics in 1997.

Your Recent History

Delayed Upgrade Clock